Navigation Links
Discovery Labs Reports Third Quarter 2013 Financial Results

WARRINGTON, Pa., Nov. 12, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2013, as well as recent business updates. The Company will host a conference call Wednesday morning, November 13, 2013 at 10:00 AM ET.  Conference call details are below.

Key updates include:

  • SURFAXIN®:  On October 4, 2013, the U.S. Food and Drug Administration (FDA) agreed to the Company's updated product specifications for SURFAXIN (lucinactant) Intratracheal Suspension.  SURFAXIN is the first FDA-approved synthetic, peptide containing surfactant available for the prevention of respiratory distress syndrome (RDS) in premature infants and the only approved alternative to animal-derived surfactants currently available today in the U.S. On November 8, 2013, the Company announced that it has initiated the commercial introduction of SURFAXIN in the U.S.
  • AEROSURF®:  In October 2013, the Company submitted an investigational new drug (IND) application to the FDA to initiate its AEROSURF phase 2 clinical program.  The FDA has completed its review and cleared the IND, and the Company can now proceed with its phase 2 clinical program.  AEROSURF is a novel investigational drug-device combination product being developed to deliver the Company's KL4 surfactant in aerosolized form to premature infants with RDS.  AEROSURF could potentially provide neonatologists with the ability to avoid invasive procedures and thereby enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy and currently are not treated.  The Company anticipates results from the first phase of its AEROSURF phase 2 clinical program in mid-2014.
  • Financial Update:  As of September 30, 2013, the Company reported cash and cash equivalents of $21.2 million.  In November 2013, the Company completed a public offering of its common stock that resulted in net proceeds, including amounts expected from an over-allotment recently exercised by the underwriters, of approximately $54 million.  Additionally, with the initiation of the commercial launch of SURFAXIN, the Company became eligible under its secured loan facility with Deerfield Management Co., L.P. (Deerfield) to receive an additional advance of $20 million, which is expected in early December 2013.
  • "With the commercial introduction of SURFAXIN, initiation of our clinical program for AEROSURF and our strengthened financial position, we are a much stronger company and better positioned to implement our business plan and achieve our vision of advancing a new standard of care for premature infants with RDS," commented John G. Cooper, President and Chief Executive Officer at Discovery Labs. 

    Summary Financial Results for the Third Quarter Ended September 30, 2013

    For the quarter ended September 30, 2013, the Company reported a net loss of $12.2 million ($0.22 basic net loss per share) on 54.8 million weighted-average common shares outstanding, compared to a net loss of $13.3 million ($0.31 basic net loss per share) on 43.4 million weighted-average common shares outstanding for the same period in 2012.  Included in the net loss is the change in fair value of certain common stock warrants that are classified as derivative liabilities, resulting in a non-cash loss of $1.1 million and $3.3 million in 2013 and 2012, respectively.

    The Company reported an operating loss of $10.8 million for the quarter ended September 30, 2013 compared to an operating loss of $10.0 million for the same period in 2012.  Net cash outflows before financing activities for the quarter ended September 30, 2013 were $10.1 million compared to $9.9 million for the same period in 2012.  The operating loss for the quarter ended September 30, 2013 includes a $1.3 million investment to prepare for the AEROSURF phase 2 clinical trials.As of September 30, 2013, the Company had cash and cash equivalents of $21.2 million. On November 5, 2013, the Company completed a public offering of 25 million shares of common stock at a price of $2.00 per share, resulting in net proceeds to the Company (after underwriting discount and anticipated expenses) of approximately $46.8 million.  The Company also granted the underwriters a 30-day option to purchase up to an additional 3.75 million shares of common stock at an offering price of $2.00 to cover over-allotments, if any.  On November 8, 2013, the underwriter notified the Company that it has exercised its over-allotment option to purchase 3.75 million additional shares of common stock.  The exercise of the option is expected to close on or about November 14, 2013 and result in net proceeds (after underwriting discount) of approximately $7.1 million.

    Additionally, with the commercial introduction of SURFAXIN, the Company became eligible under its  $30 million secured loan facility with Deerfield to receive the final $20 million advance, which is expected on or about December 3, 2013.  The initial $10 million was advanced in February 2013 upon execution of the facility agreement.  In connection with the $20 million advance, Deerfield will receive a transaction fee equal to 1.5% of the advance, and warrants to purchase approximately 4.7 million shares of common stock at an exercise price of $2.81 per share.

    In October 2013, the Company initiated an offering under its at-the-market (ATM) Program with Stifel, Nicolaus & Company, Incorporated and issued 713,920 shares of common stock at an average price per share of $2.75, resulting in net proceeds (after a 3% commission) of approximately $1.9 million.  Following this offering, approximately $23.1 million remains available under the Company's ATM Program. 

    For the fourth quarter of 2013, the Company anticipates operating cash outflows before financing activities of $10.5 million, and approximately $85 million in cash and cash equivalents at December 31, 2013.

    As of September 30, 2013, the Company reported a common stock warrant liability of $4.7 million, predominantly related to five-year warrants issued in February 2011.  These warrants are not subject to cash settlement; however, they have been classified as derivative liabilities in accordance with generally accepted accounting principles because they contain anti-dilution provisions that adjust the exercise price of the warrants in certain circumstances. 

    The Company had 54.9 and 43.7 million shares of common stock outstanding as of September 30, 2013 and December 31, 2012, respectively.  The Company currently has 80.7 million shares of common stock outstanding, not including 3.75 million shares to be issued upon closing of underwriters' over-allotment option.

    Readers are referred to, and encouraged to read in their entirety the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 filed with the Securities and Exchange Commission, which includes further detail on the above-referenced transactions and the Company's business plans and operations, financial condition and results of operations.

    Conference Call and Audio Webcast Details 
    Discovery Labs will hold a conference call and audio webcast on Wednesday, November 13, 2013 at 10:00 AM ET to discuss the foregoing. To access the conference call and participate in the question-and-answer session, the number for domestic callers is (877) 870-4263 and for international callers (412) 317-0790.  The conference call replay number is (877) 344-7529 or (412) 317-0088. The passcode for the replay is 10036729.

    The audio webcast of the conference call will be available at and the Discovery Labs website at  It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call.
    A replay of the audio webcast will be available after the call at the Company's website.

    About SURFAXIN®
    The U.S. Food and Drug Administration (FDA) approved SURFAXIN® (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants who are at high risk for RDS.  SURFAXIN is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal derived surfactants.

    SURFAXIN is intended for intratracheal use only.  The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance.  SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting.  Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

    Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. 

    SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

    For more information about SURFAXIN, please visit

    About AEROSURF®
    AEROSURF is a novel investigational drug-device combination product being developed to deliver Discovery Labs' KL4 surfactant in aerosolized form to premature infants with respiratory distress syndrome (RDS).  AEROSURF could potentially allow for the administration of KL4 surfactant to premature infants without invasive endotracheal intubation, and may enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

    About Discovery Labs
    Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care.  Discovery Labs' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

    For more information, please visit the Company's website at

    Forward-Looking Statements
    To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results, including projections of future cash balances and anticipated cash outflows, to differ materially from the statements made.  Examples of such risks and uncertainties include: risks relating to efforts to commercialize SURFAXIN and AFECTAIR, including (1) whether Discovery Labs' commercial and medical affairs organizations will succeed in introducing the products, (2) whether the products will be approved by hospitals and will gain market acceptance and be preferred by healthcare providers over current products, (3) whether the products will generate revenues sufficient to fund Discovery Labs' research and development activities and support its operations, and (4) whether Discovery Labs will successfully develop a planned second vial size for SURFAXIN and follow-on AFECTAIR devices; risks related to development programs, including in particular the AEROSURF development program, including time-consuming and expensive pre-clinical studies and clinical trials, which may be subject to potentially significant delays or regulatory holds, or fail; risks that Discovery Labs will be unable to secure significant additional capital as needed, and may be unable in a timely manner, if at all, to identify potential strategic partners to support product development and, if approved, commercialize products in markets outside the U.S., or to access debt or equity financings, which could result in substantial equity dilution; risks related to technology transfers to contract manufacturers and problems or delays encountered by Discovery Labs, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol-conducting airway connectors, CAG devices and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with Discovery Labs on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of Discovery Labs' products, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals; other risks, including those related to (1) continued compliance with The Nasdaq Capital Market listing requirements, (2) Discovery Labs' efforts to maintain and protect the patents and licenses related to its products, (3) whether it or its strategic partners will be able to attract and retain qualified personnel, (3) other companies' competing products, (3) legal proceedings, and (4) health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.  

    Condensed Consolidated Statement of Operations
    (in thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30(unaudited)(unaudited)2013201220132012Revenue from collaborative arrangement and grants

    8211;Operating expenses: (1)Research and development

    6,5745,74321,90915,482Selling, general and administrative

    4,2994,25512,6489,912Total expenses

    10,8739,99834,55725,394Operating loss


    Change in fair value of common stock warrant liability

    (1,059)(3,309)1,627(5,063)Interest and other income / (expense), net

    (352)(39)(871)(43)Net loss

    (30,500)Net loss per common share:Basic


    (0.80)Weighted avg. common shares outstanding:Basic



    Includes non-cash charges for depreciation and stock-based compensation of $0.8 million ($0.4 million in R&D and $0.4 million in SG&A) for each of  the three months ended September 30, 2013 and 2012; and for the nine months ended September 30, 2013 and 2012, $2.1 million ($1.1 million in R&D and $1.0 million in SG&A) and $2.1 million ($1.2 million in R&D and $0.9 million in SG&A), respectively. 



    Discovery Laboratories, IncCondensed Consolidated Balance Sheets
    (in thousands)September 30,December 31,20132012ASSETS(Unaudited)Current Assets:Cash and cash equivalents


    117195Prepaid expenses and other current assets

    418719Total current assets

    21,71227,806Property and equipment, net

    1,4171,737Restricted cash and other assets

    502400Total Assets

    29,943LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    ,166Accrued expenses

    5,0714,159Common stock warrant liability

    4,6786,305Equipment loan and capitalized leases, current portion

    7269Total Current Liabilities

    11,31011,699Long-Term Liabilities:Long-term debt, net of discount of $3.7 million at September 30, 2013 and $0 at December 31, 2012, respectively

    6,326–Equipment loan, non-current portion & other liabilities

    520591Total Liabilities

    18,15612,290Stockholders' Equity:

    5,47517,653Total Liabilities and Stockholders' Equity


    SOURCE Discovery Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
    2. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
    3. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
    4. Discovery Labs Announces Completion of $50 Million Public Offering
    5. Discovery Labs Prices $50 Million Public Offering of Common Stock
    6. Discovery Labs Announces Proposed Public Offering of Common Stock
    7. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
    8. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
    9. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
    10. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
    11. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
    Post Your Comments:
    (Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
    (Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
    (Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
    (Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
    Breaking Biology Technology:
    ... ... product immediately, NATICK, Mass., April 14 Boston Scientific,Corporation ... Labor,and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular,lead ... failure. The Company also received reimbursement approval for,the lead from ...
    ... SGP ) is scheduled to announce its sales and ... 23, 2008., At 8 a.m. (EDT) on that ... for the 2008 first quarter and provide an update ... Fred Hassan,Schering-Plough,s chairman and CEO, and other members of ...
    ... For 88 percent of,companies, front-line and mid-level leaders ... variety of development skills but focus,strongly on techniques ... only half of executive-level sales leaders attend the ... and,training, according to a member-driven research study conducted ...
    Cached Biology Technology:
    (Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
    (Date:9/10/2015)... Sept. 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... site, Touch of Modern, will feature the Wocket® smart ... th . Touch Of Modern ... designer lifestyle products to its 7.2 million members. Customers ...
    (Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
    Breaking Biology News(10 mins):
    ... -- A team of scientists led by Washington University in ... corn, a crop vital to U.S. agriculture. The researchers have ... that should accelerate efforts to develop better crop varieties to ... , Corn, also known as maize, underlies myriads of ...
    ... past year, various reports from the United Nations Intergovernmental Panel ... uncertain terms that in order to achieve a stable climate ... increase in CO2 emissions in the coming decades must be ... the IPCC, the maxi-mum amount of CO2 emissions that can ...
    ... do nearly 1 million people taking cholesterol-lowering statins often ... rare case when a diabetic takes medication for intestinal ... basis for the purported health effects of green tea? ... clinical explanation for these and other physiological mysteries. The ...
    Cached Biology News:
    Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
    Synaptotagmin, phosphoSer309...
    ... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
    Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
    Biology Products: